FDA Adverse Event Injury Summary report: N

ESSURE

MDR report key: 4322789 · Received December 11, 2014

Report

Report Number
2951250-2014-00523
Event Type
Injury
Date Received
December 11, 2014
Report Date
January 19, 2017
Manufacturer
BAYER PHARMA AG
Product Code
HHS
PMA / PMN Number
P020014
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
OTHER

Narratives

Description of Event or Problem · 1

THIS IS A SPONTANEOUS CASE REPORT RECEIVED FROM A CONSUMER IN (B)(6) ON (B)(6) 2014 WHICH REFERS TO HERSELF WHO HAD ESSURE (FALLOPIAN TUBE OCCLUSION INSERT) INSERTED. CONSUMER REPORTED VIA SOCIAL MEDIA THAT ESSURE TOOK HER TUBES (BILATERAL SALPINGECTOMY), THEN HER UTERUS (HYSTERECTOMY). PTC INVESTIGATION RESULT RECEIVED ON 03-DEC-2014. PTC GLOBAL NUMBER (B)(4). FINAL ASSESSMENT: SINCE NO PRODUCT WAS RETURNED TO US FOR INVESTIGATION, WE WERE UNABLE TO PERFORM AN INVESTIGATION OF THE ACTUAL DEVICE INVOLVED IN THIS COMPLAINT. TYPICALLY, WE WOULD INSPECT THE MICRO-INSERT TO CONFIRM THAT ALL PARTS ARE ACCOUNTED FOR AND INSPECT THE DEVICE TO LOOK FOR ANY MANUFACTURING DEFICIENCIES. SINCE WE HAVE NO VALID LOT NUMBER FOR THIS CASE, WE WERE UNABLE TO CONDUCT A REVIEW OF THE MANUFACTURING BATCH RECORD. WE ARE UNABLE TO CONFIRM ANY QUALITY DEFECT OR DEVICE MALFUNCTION AT THIS TIME. THIS IS AN ANTICIPATED EVENT. MEDICAL ASSESSMENT: THIS PTC WAS INITIATED DUE TO A REQUEST FOR CONFIRMATION OF QUALITY. THE REPORTED ADVERSE EVENTS ARE KNOWN, POSSIBLE, UNDESIRABLE EVENTS AND NOT INDICATIVE OF A QUALITY DEFICIT PER SE. NO BATCH NUMBER WAS REPORTED. WITHOUT THIS INFORMATION NO BATCH SIGNAL CLUSTER REVIEW IN THE GPV DATABASE FOR A MORE DETAILED STATISTICAL MEDICAL EVALUATION IS POSSIBLE. NO COMPLAINT SAMPLE WAS PROVIDED FOR A TECHNICAL INVESTIGATION. THE TECHNICAL ASSESSMENT CONCLUDED UNCONFIRMED QUALITY DEFECT. IN SUMMARY, THERE IS NO REASON TO SUSPECT A CAUSAL RELATIONSHIP TO A POTENTIAL QUALITY DEFICIT. THE LIST OF SIMILAR CASES CONTAINS REPORTS WITH SIMILAR EVENTS CODED IN MEDDRA. IT INCLUDES RECENT CASES RECEIVED BY BAYER PHARMA AND OLDER CASES RECEIVED FROM THE PREVIOUS OWNER OF THE ESSURE PRODUCT (CONCEPTUS). THESE LEGACY REPORTS HAVE BEEN RE-CODED ACCORDING TO BAYER PHARMA STANDARDS. IN THIS PARTICULAR CASE A SEARCH IN THE DATABASE WAS PERFORMED ON (B)(6) 2014 FOR THE FOLLOWING MEDDRA PREFERRED TERMS: SALPINGECTOMY: THE ANALYSIS IN THE GLOBAL SAFETY DATABASE REVEALED (B)(4) CASES. HYSTERECTOMY: THE ANALYSIS IN THE GLOBAL SAFETY DATABASE REVEALED (B)(4) CASES. BAYER IS CLOSELY MONITORING THE BENEFIT-RISK PROFILE OF ESSURE. THIS INCLUDES CONSIDERATION OF THE LEGACY CASES IN SAFETY ANALYSES. THE CUMULATIVE REVIEW OF THE REPORTS HAS NOT YIELDED ANY NEW SAFETY SIGNAL." COMPANY CAUSALITY COMMENT: THIS NON-MEDICALLY CONFIRMED, SOCIAL MEDIA CASE REPORT REFERS TO A FEMALE CONSUMER WHO HAD ESSURE (FALLOPIAN TUBE OCCLUSION INSERT) INSERTED AND ESSURE TOOK HER TUBES (BILATERAL SALPINGECTOMY), THEN HER UTERUS (HYSTERECTOMY). THE REPORTED EVENTS WERE CONSIDERED SERIOUS, DUE TO MEDICAL IMPORTANCE AND ARE LISTED IN ESSURE'S REFERENCE SAFETY INFORMATION. IF, AFTER ESSURE INSERTION, REMOVAL OF THE MICRO-INSERT IS NECESSARY, SURGERY (SALPINGECTOMY OR HYSTERECTOMY) MAY BE REQUIRED. IN THIS PARTICULAR CASE, ALTHOUGH THE EXACT REASON FOR ESSURE REMOVAL WAS NOT SPECIFIED, SINCE REPORTER REGARDED THE EVENTS AS A CONSEQUENCE OF ESSURE USE AND NO FOLLOW-UP WILL BE POSSIBLE (SOCIAL MEDIA CASE); COMPANY CONSIDERS A CAUSAL RELATIONSHIP BETWEEN THE REPORTED EVENTS AND ESSURE THERAPY CANNOT BE EXCLUDED AND DUE TO THE INTERVENTIONS THIS CASE WAS CONSIDERED AN INCIDENT. THE PRODUCT TECHNICAL ANALYSIS CONCLUDED UNCONFIRMED QUALITY DEFECT. THERE IS NO REASON TO SUSPECT A CAUSAL RELATIONSHIP TO A POTENTIAL QUALITY DEFICIT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
806338 ESSURE INSERT, TUBAL OCCLUSION HHS BAYER PHARMA AG ESS305

Patients

Seq Age Sex Outcome Treatment
1 Other| R